Info
2022.12.22
Presentation of Phase 2 STEMTRA Trial Results at The 14th World Congress on Brain Injury
News Release
2022.12.21
Establishment of In-House Facility and Acquisition of License for Packaging, Labeling and Storage of Regenerative Medicine Products
News Release
2022.11.29
Joint Research Agreement for SB623 Targeting Alzheimer’s-Type Dementia
News Release
2022.12.21
Establishment of In-House Facility and Acquisition of License for Packaging, Labeling and Storage of Regenerative Medicine Products
News Release
2022.11.29
Joint Research Agreement for SB623 Targeting Alzheimer’s-Type Dementia
News Release
2022.10.20
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
Media
2022.04.08
On April 7, NeurologyLive published an interview with Dr. Peter McAllister regarding the final analysis of the Phase 2 STEMTRA trial.
Media
2018.04.20
Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio, publishes report in the leading medical journal, Stroke
Info
2022.12.22
Presentation of Phase 2 STEMTRA Trial Results at The 14th World Congress on Brain Injury
Info
2021.02.22
Head of Regulatory Affairs Japan, Kazumi Sawaguchi, Ph.D., gave a presentation at 5th DIA Cell and Gene Therapy Products Symposium in Japan
Info
2021.01.06
SanBio to Present at the 39th Annual J.P. Morgan Healthcare Conference
SanBio works to develop pharmaceuticals, such as SB623, that can be delivered to patients all over the world. SB623 represents just the first step in this effort, but we believe it will serve as a foundation on which we can build to support the health of a large number of patients in the future.